Clinical concomitant benefits on pelvic floor dysfunctions after sacral neuromodulation in XXXX with incomplete @entity1566 .

@entity1 @entity3501 @entity323 @entity322 @entity29943 @entity1566
OBJECTIVES: To assess the concomitant clinical improvement in incomplete @entity1566 @entity1 (SCIPs) suffering from @entity3501 ( @entity3501 ), neurogenic lower urinary tract symptoms (NLUTSs) and @entity323 ( @entity323 ) using sacral neuromodulation (SNM) for @entity3501 and NLUTSs. METHODS: Seventy-five SCIPs were selected. Before and during the follow-ups post-SNM, NLUTSs and @entity3501 were detected mainly through specific diaries. Erectile function was assessed using the International Index of Erectile Function composed of 5 questions (IIEF5). Quality of life (QoL) was measured with the Short Form 36 Health Survey questionnaire (SF-36). During the first stage, in which a permanent electrode was inserted percutaneously into the third sacral foramina and stimulated using an external generator, @entity1 with @entity3501 or NLUTSs were required to improve their symptoms by at least 50% compared with baseline before proceeding to the second stage in which the generator was placed in the @entity1 's buttock. @entity323 @entity1 needed to increase their IIEF5 score by at least 25% compared with baseline (evaluated initially 3 months after the second stage) in order to continue follow-up. RESULTS: Fourteen out of 37 subjects who manifested two functional pelvic dysfunctions at baseline maintained notable clinical improvement in two pelvic functions (median follow-up >3 years). Six had non-obstructive retention (NOR) and @entity323 , six double @entity322 , and two constipation with NOR. In the general and mental health domains of the SF-36, all @entity1 improved their scores by at least 20% compared with baseline. CONCLUSIONS: SNM may be beneficial to selected incomplete @entity29943 with concomitant pelvic functional disturbances.
